| Kevin Smith, MD | |
|
862 Callen Lane Nw, Suite 110, Cleveland, TN 37312-3784 | |
| (423) 331-5025 | |
| (423) 698-0511 |
| Full Name | Kevin Smith |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 29 Years |
| Location | 862 Callen Lane Nw, Cleveland, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205898137 | NPI | - | NPPES |
| 99578531 | Medicaid | CO | |
| Q06091 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207LP2900X | Anesthesiology - Pain Medicine | 61375 (Tennessee) | Primary |
| 207L00000X | Anesthesiology | 37926 (Colorado) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Specialist In Pain Management Pc | 1355253659 | 10 |
| Stephen V. Dreskin Md Pc | 2163491747 | 7 |
| Sda Consultants Pllc | 3870825912 | 16 |
News Archive
Upsher-Smith Laboratories, Inc. announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of USL261, an investigational intranasal midazolam, for the rescue treatment of seizures in patients on stable anti-epileptic drug (AED) regimens who require control of intermittent bouts of increased seizure activity, frequently referred to as seizure clusters. USL261 has been granted orphan drug designation for this use by the Food and Drug Administration (FDA).
Neoprobe Corporation a diversified developer of innovative oncology surgical and diagnostic products, today announced that Senior Vice President of Pharmaceutical Research and Clinical Development, Dr. Frederick O. Cope, presented information on the Company's lead pipeline initiative, Lymphoseek, at the International Symposium on Technetium and Other Radiometals in Chemistry and Medicine (TERACHEM), held September 8-11, 2010 in Bressanone (Bolzano), Italy.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, and Patheon Inc., a global provider of drug development and manufacturing services, announced today a long-term agreement for commercial manufacturing of Contrave® (naltrexone HCL sustained release (SR)/bupropion HCL SR) as well as development of future formulations of Orexigen products.
QBC Diagnostics was awarded one of the largest contracts in company history, as the United States Navy has agreed to install QBC STAR hematology analyzers on surface ships throughout the world.
› Verified 6 days ago
| Entity Name | Stephen V. Dreskin Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619056462 PECOS PAC ID: 2163491747 Enrollment ID: O20040930000145 |
News Archive
Upsher-Smith Laboratories, Inc. announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of USL261, an investigational intranasal midazolam, for the rescue treatment of seizures in patients on stable anti-epileptic drug (AED) regimens who require control of intermittent bouts of increased seizure activity, frequently referred to as seizure clusters. USL261 has been granted orphan drug designation for this use by the Food and Drug Administration (FDA).
Neoprobe Corporation a diversified developer of innovative oncology surgical and diagnostic products, today announced that Senior Vice President of Pharmaceutical Research and Clinical Development, Dr. Frederick O. Cope, presented information on the Company's lead pipeline initiative, Lymphoseek, at the International Symposium on Technetium and Other Radiometals in Chemistry and Medicine (TERACHEM), held September 8-11, 2010 in Bressanone (Bolzano), Italy.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, and Patheon Inc., a global provider of drug development and manufacturing services, announced today a long-term agreement for commercial manufacturing of Contrave® (naltrexone HCL sustained release (SR)/bupropion HCL SR) as well as development of future formulations of Orexigen products.
QBC Diagnostics was awarded one of the largest contracts in company history, as the United States Navy has agreed to install QBC STAR hematology analyzers on surface ships throughout the world.
› Verified 6 days ago
| Entity Name | Specialist In Pain Management Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447203922 PECOS PAC ID: 1355253659 Enrollment ID: O20041022000859 |
News Archive
Upsher-Smith Laboratories, Inc. announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of USL261, an investigational intranasal midazolam, for the rescue treatment of seizures in patients on stable anti-epileptic drug (AED) regimens who require control of intermittent bouts of increased seizure activity, frequently referred to as seizure clusters. USL261 has been granted orphan drug designation for this use by the Food and Drug Administration (FDA).
Neoprobe Corporation a diversified developer of innovative oncology surgical and diagnostic products, today announced that Senior Vice President of Pharmaceutical Research and Clinical Development, Dr. Frederick O. Cope, presented information on the Company's lead pipeline initiative, Lymphoseek, at the International Symposium on Technetium and Other Radiometals in Chemistry and Medicine (TERACHEM), held September 8-11, 2010 in Bressanone (Bolzano), Italy.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, and Patheon Inc., a global provider of drug development and manufacturing services, announced today a long-term agreement for commercial manufacturing of Contrave® (naltrexone HCL sustained release (SR)/bupropion HCL SR) as well as development of future formulations of Orexigen products.
QBC Diagnostics was awarded one of the largest contracts in company history, as the United States Navy has agreed to install QBC STAR hematology analyzers on surface ships throughout the world.
› Verified 6 days ago
| Entity Name | Cleveland Anesthesiologists Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962483552 PECOS PAC ID: 1850296823 Enrollment ID: O20060201000458 |
News Archive
Upsher-Smith Laboratories, Inc. announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of USL261, an investigational intranasal midazolam, for the rescue treatment of seizures in patients on stable anti-epileptic drug (AED) regimens who require control of intermittent bouts of increased seizure activity, frequently referred to as seizure clusters. USL261 has been granted orphan drug designation for this use by the Food and Drug Administration (FDA).
Neoprobe Corporation a diversified developer of innovative oncology surgical and diagnostic products, today announced that Senior Vice President of Pharmaceutical Research and Clinical Development, Dr. Frederick O. Cope, presented information on the Company's lead pipeline initiative, Lymphoseek, at the International Symposium on Technetium and Other Radiometals in Chemistry and Medicine (TERACHEM), held September 8-11, 2010 in Bressanone (Bolzano), Italy.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, and Patheon Inc., a global provider of drug development and manufacturing services, announced today a long-term agreement for commercial manufacturing of Contrave® (naltrexone HCL sustained release (SR)/bupropion HCL SR) as well as development of future formulations of Orexigen products.
QBC Diagnostics was awarded one of the largest contracts in company history, as the United States Navy has agreed to install QBC STAR hematology analyzers on surface ships throughout the world.
› Verified 6 days ago
| Entity Name | Sda Consultants Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336605500 PECOS PAC ID: 3870825912 Enrollment ID: O20220421002076 |
News Archive
Upsher-Smith Laboratories, Inc. announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of USL261, an investigational intranasal midazolam, for the rescue treatment of seizures in patients on stable anti-epileptic drug (AED) regimens who require control of intermittent bouts of increased seizure activity, frequently referred to as seizure clusters. USL261 has been granted orphan drug designation for this use by the Food and Drug Administration (FDA).
Neoprobe Corporation a diversified developer of innovative oncology surgical and diagnostic products, today announced that Senior Vice President of Pharmaceutical Research and Clinical Development, Dr. Frederick O. Cope, presented information on the Company's lead pipeline initiative, Lymphoseek, at the International Symposium on Technetium and Other Radiometals in Chemistry and Medicine (TERACHEM), held September 8-11, 2010 in Bressanone (Bolzano), Italy.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, and Patheon Inc., a global provider of drug development and manufacturing services, announced today a long-term agreement for commercial manufacturing of Contrave® (naltrexone HCL sustained release (SR)/bupropion HCL SR) as well as development of future formulations of Orexigen products.
QBC Diagnostics was awarded one of the largest contracts in company history, as the United States Navy has agreed to install QBC STAR hematology analyzers on surface ships throughout the world.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kevin Smith, MD 281 N Lyerly St Ste 200, Chattanooga, TN 37404-2728 Ph: (423) 688-0850 | Kevin Smith, MD 862 Callen Lane Nw, Suite 110, Cleveland, TN 37312-3784 Ph: (423) 331-5025 |
News Archive
Upsher-Smith Laboratories, Inc. announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of USL261, an investigational intranasal midazolam, for the rescue treatment of seizures in patients on stable anti-epileptic drug (AED) regimens who require control of intermittent bouts of increased seizure activity, frequently referred to as seizure clusters. USL261 has been granted orphan drug designation for this use by the Food and Drug Administration (FDA).
Neoprobe Corporation a diversified developer of innovative oncology surgical and diagnostic products, today announced that Senior Vice President of Pharmaceutical Research and Clinical Development, Dr. Frederick O. Cope, presented information on the Company's lead pipeline initiative, Lymphoseek, at the International Symposium on Technetium and Other Radiometals in Chemistry and Medicine (TERACHEM), held September 8-11, 2010 in Bressanone (Bolzano), Italy.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, and Patheon Inc., a global provider of drug development and manufacturing services, announced today a long-term agreement for commercial manufacturing of Contrave® (naltrexone HCL sustained release (SR)/bupropion HCL SR) as well as development of future formulations of Orexigen products.
QBC Diagnostics was awarded one of the largest contracts in company history, as the United States Navy has agreed to install QBC STAR hematology analyzers on surface ships throughout the world.
› Verified 6 days ago
Dennis C. Ford, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2020 Keith St Nw, Ste C, Cleveland, TN 37311 Phone: 423-614-0535 Fax: 423-614-0545 | |
Cynthia M. Niendorff, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 102 Dunhill Pl Nw, Cleveland, TN 37311 Phone: 423-339-9581 Fax: 423-472-0454 | |
James Fancis Hannifin, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 2080 Chambliss Ave Nw, Cleveland Anesthesiologists Inc, Cleveland, TN 37311 Phone: 423-472-6514 Fax: 423-476-2062 | |
Paul E Pinson, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3917 Georgetown Rd Nw, Cleveland, TN 37312 Phone: 423-803-3830 Fax: 423-402-8550 | |
Dr. Ryan Bearer, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 862 Callen Lane Nw, Suite 110, Cleveland, TN 37312 Phone: 423-331-5025 Fax: 423-698-0511 | |
Philip Dale Lowry, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 2080 Chambliss Ave, Suite 1, Cleveland, TN 37311 Phone: 423-472-6513 Fax: 423-476-2062 |